Clinical Trial Update: Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

View source ↗

Summary

A National Eye Institute-sponsored clinical trial investigating STDG3-related Stargardt-like macular dystrophy due to ELOVL4 mutations is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt-like Macular Dystrophy

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Stargardt-Like Macular Dystrophy | Status: RECRUITING